

# David A Cox

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8163937/publications.pdf>

Version: 2024-02-01

10  
papers

215  
citations

1477746

6  
h-index

1372195

10  
g-index

10  
all docs

10  
docs citations

10  
times ranked

137  
citing authors

#	ARTICLE	IF	CITATIONS
1	Efficacy and Safety of Dulaglutide 3.0 mg and 4.5 mg Versus Dulaglutide 1.5 mg in Metformin-Treated Patients With Type 2 Diabetes in a Randomized Controlled Trial (AWARD-11). <i>Diabetes Care</i> , 2021, 44, 765-773.	4.3	91
2	Once-Weekly Dulaglutide for the Treatment of Youths with Type 2 Diabetes. <i>New England Journal of Medicine</i> , 2022, 387, 433-443.	13.9	43
3	Efficacy and safety of an expanded dulaglutide dose range: A phase 2, placebo-controlled trial in patients with type 2 diabetes using metformin. <i>Diabetes, Obesity and Metabolism</i> , 2019, 21, 2048-2057.	2.2	26
4	Effect of dulaglutide 3.0 and 4.5 mg on weight in patients with type 2 diabetes: Exploratory analyses of AWARD-11. <i>Diabetes, Obesity and Metabolism</i> , 2021, 23, 2242-2250.	2.2	23
5	Gastrointestinal Tolerability of Once-Weekly Dulaglutide 3.0 mg and 4.5 mg: A Post Hoc Analysis of the Incidence and Prevalence of Nausea, Vomiting, and Diarrhea in AWARD-11. <i>Diabetes Therapy</i> , 2021, 12, 2783-2794.	1.2	8
6	Effect of raloxifene on the incidence of elevated low density lipoprotein (LDL) and achievement of LDL target goals in postmenopausal women. <i>Current Medical Research and Opinion</i> , 2004, 20, 1049-1055.	0.9	7
7	Efficacy and safety of dulaglutide 3.0 and 4.5 mg in patients aged younger than 65 and 65 years or older: Post hoc analysis of the AWARD-11 trial. <i>Diabetes, Obesity and Metabolism</i> , 2021, 23, 2279-2288.	2.2	6
8	A Review of Interventional Trials in Youth-Onset Type 2 Diabetes: Challenges and Opportunities. <i>Diabetes Therapy</i> , 2021, 12, 2827-2856.	1.2	6
9	Effect of expanded dulaglutide weekly doses (3.0 mg and 4.5 mg) on cardiovascular disease risk factors in participants with type 2 diabetes at increased cardiovascular disease risk: a post hoc analysis of the AWARD-11 study. <i>Diabetes, Obesity and Metabolism</i> , 2022, , .	2.2	3
10	Glycaemic efficacy of an expanded dose range of dulaglutide according to baseline glycated haemoglobin (HbA1c) subgroup: Post hoc analysis of AWARD-11. <i>Diabetes, Obesity and Metabolism</i> , 2021, 23, 2819-2824.	2.2	2